- 17Volume 4, 2021Nov 18, Issue 20Expanding the Potential Benefit of anti-CTLA-4 in Pancreatic Cancer Through a Clinical CollaborationNov 05, Issue 19Sep 22, Issue 18Sep 09, Issue 17Aug 26, Issue 16Jul 20, Issue 14Jun 02, Issue 11May 19, Issue 10May 04, Issue 9Apr 20, Issue 8Apr 06, Issue 7Mar 23, Issue 6Mar 09, Issue 5Feb 23, Issue 4Feb 09, Issue 3Jan 26, Issue 2
- 16Volume 3, 2020Dec 15, Issue 25Dec 01, Issue 24Nov 17, Issue 23Oct 06, Issue 20Sep 08, Issue 18Aug 25, Issue 17Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
Tune in today at 1:50PM ET for our fireside chat by @garo_armen and @ODayMD at the annual Evercore ISI HealthCONX Conference: wsw.com/webcast/everco…
The latest Agenus Newsletter is now available! AGEN1181 Achieves Responses Across 9 Cancers: Seventeen Objective Responses as Single Agent or in Combination with Balstilimab agenusbio.com/newsletters/ag…
Tune in today to hear @dhanschand and @ODayMD at the B. Riley Fall 2021 Growth Biotech Best Ideas Series, including the latest #AGEN1181 clinical data from #SITC21 investor.agenusbio.com/events/event-d…
#AGEN1181 demonstrates clinical responses across nine treatment-resistant cancers at #SITC21 #oncology #Immunotherapy investor.agenusbio.com/news-releases/…
MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797 investor.minktherapeutics.com/news-releases/… #SITC21 Retweeted by Agenus Inc. ($AGEN)
Hear @ODayMD and @DrMhidalgo discuss the latest #AGEN1181 Phase 1 data from #SITC21 in a webcast hosted by William Blair. investor.agenusbio.com/events/event-d…
Our #SITC21 abstract summarizing #AGEN1181 data from >100 patients treated is live! #AGEN1181 +/- balstilimab shows durable responses in 9 cancer types, including patients who have failed PD-1 therapy; Ph2/3 to commence in colorectal and GYN cancers. jitc.bmj.com/content/9/Supp…
See $AGEN full Q3 2021 earnings report and corporate update here: investor.agenusbio.com/news-releases/…
Agenus Provides Update on Balstilimab Development investor.agenusbio.com/news-releases/…
Today, we took another step in advancing our immuno-oncology therapies to cancer patients. We announced that the first patient has been dosed with AGEN1777, our first-in-class #TIGIT bispecific licensed to @bmsnews, triggering a $20M milestone payment. investor.agenusbio.com/news-releases/…
WHO recommends broader use of the world’s first malaria vaccine, containing Agenus’ QS-21 Stimulon. Read today’s story from @BosBizJournal. @garo_armen bizjournals.com/boston/news/20…
Yesterday, @WHO rec. widespread use of the 1st malaria vaccine to young children in sub-Saharan Africa —what made the news more interesting was the fact that it was a 27-yr old biotech in Lexington that made the vaccine possible. @garo_armen @Agenus_Bio bit.ly/2YvXHgk Retweeted by Agenus Inc. ($AGEN)
Live from #BioFuture21, @jbuell01 discusses the future of cancer treatment and emerging areas of innovation in oncology
Targeting ILT-4 with $AGEN discovered antibody, MK-4830, may increase the anti-tumor activity of pembrolizumab even in tumors with low levels of T-cell inflammation. Publication in Clinical Cancer Research discusses potential of ILT-4 blockade to abrogate PD-1/PD-L1 resistance twitter.com/CCR_AACR/statu…
Antibody MK-4830 alone or in combination with #pembrolizumab shows antitumor activity and presents the potential for a new mechanism to treat anti–PD-1/PD-L1 resistance. https://t.co/wFb1Zq4Wb7.@lillian_siu pic.twitter.com/EHLBNvSGC2
— Clinical Cancer Research (@CCR_AACR) October 5, 2021
Tune in today, at 1:30pm EST, to hear @jbuell01 speak at the BioFuture 2021 panel, “Next Gen Oncology Therapeutics: Changing the Cancer Landscape.” biofuture.com/biofuture-regi…
Oh the talent density @Agenus_Bio and @MiNK_iNKT! twitter.com/jbuell01/statu…
Saturday I-O University w practice-changing giant @ODayMD; sharing lessons from curing melanomas to #conquer other cancers. The best part is… he’s on our team @Agenus_Bio! #cancer #Immunology pic.twitter.com/ulIBSgbkzm
— Jennifer Buell (@jbuell01) October 2, 2021
Agenus to Present AGEN1181 Clinical Data at SITC investor.agenusbio.com/news-releases/…
September is #GynecologicCancerAwarenessMonth and we at $AGEN are committed to fighting gynecologic cancers by advancing important therapeutic options for patients, spreading awareness, and encouraging education.
Bal/Zal Doubles Responses Compared to Currently Available Therapies at #ESMO21 Data demonstrate the power of our combo approach to improve patient outcomes and address difficult tumors, while remaining well-tolerated for patients. Today's Newsletter: agenusbio.com/newsletters/ag…